Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
Fiche publication
Date publication
janvier 2021
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Pr PETIT Thierry
Tous les auteurs :
Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy MP, D'Hondt V, Dalenc F, Ferrero JM, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard JC, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frénel JS
Lien Pubmed
Résumé
Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far.
Mots clés
bone-only, metastatic breast cancer, outcomes, overall survival, real-life, treatments
Référence
Ther Adv Med Oncol. 2021 ;13:1758835920987657